Sutro Biopharma Net Income

Sutro Biopharma (STRO) currently reports a net income of $-180M as of June 2026. That compares with $-210M in the prior-year period — up 13.4% year over year. That is below the Healthcare sector average of $17B. Use the charts on this page to explore Sutro Biopharma's net income history and peer comparisons.

Sutro Biopharma's net income increased from $-210M to $-180M — a 13.4% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Sutro Biopharma's net income of $-180M is lower than the Healthcare sector average of $17B. That is roughly 101.1% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Sutro Biopharma reported $-180M in net income as of June 2026. That compares with $-210M in the prior-year period — up 13.4% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current net income of $-180M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $17B. From there, open related valuation or income-statement pages for Sutro Biopharma, and consider following STRO for alerts when major investors trade the stock.